DarioHealth’s Digital Therapeutics Selected as Employee Health Benefit by Self-Insured, Fortune 500 Company

Dario’s top-rated digital diabetes tools and coaching will be available to eligible employees and their dependents starting January 1, 2021

Contract awarded after RFP, highlights the strength of Dario’s digital chronic care platform relative to competitive offerings

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today that it has signed a contract to provide its digital therapeutics solution to eligible employees of a U.S.-based Fortune 500 technology company.

Dario will be available to eligible employees and dependents effective January 1, 2021, concurrent with the start of the benefits year.  Dario helps manage and improve the health of people living with chronic conditions such as diabetes and hypertension.

We believe that employees will benefit from Dario’s unique therapeutic approach, which delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching.  These employees will join a community of tens of thousands of members who engage with Dario every day to measurably improve their health.

“This contract was awarded through a request for proposal (RFP) process that included Dario’s largest competitors and we believe it represents an important milestone in our strategic shift toward the business-to-business-to-consumer (B2B2C) market comprised of self-insured employers, healthcare provider networks, and insurance plans,” commented Rick Anderson, President and GM of North America.  “We believe this further validates the competitive strength of our top-rated digital chronic care solution and will serve as an important market reference in converting our employer pipeline.”